1Reich K. The concept of psoriasis as a systemic inflammation : implications for disease management[J]. Journal of the European Academy of Dermatology andVenereology, 2012, 26(2):3-11.
8Bojke L, Epstein D, Craig D, et al. Model in the cost effectiveness of biologic treatments for psoriatic arthritis[J]. Rheumatol0gy ( Oxford ), 2011, 50 ( 4 ) : 39-47.
5Mease PJ, Kivitz A J, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumato1,2006 ,33 :712-721.
6de Vlam K,Lories RJ. Efficacy,effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford) ,2006,45 : 321-324.
7Gottlieb AB,Kircik L,Eisen D,et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care and Treatment with Etanercept(EDUCATE) study. J Dermatolog Treat,2006,17:343-352.
8Haake H, Koneke J ,Amann K ,et al. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin ( Munich ), 2007, 102 : 852-857.
9Kaey S,Worm M,Audring H,et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis, 2006,65: 405 -407.
10Antoni CE, Kavanaugh A, vander Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial(IMPACT). J Rheumatol,2008 ,35:869-876.
